MarketPulse

epilepsy treatment

2 articles
The Motley FoolThe Motley Fool··Lee Samaha

Ovid Therapeutics Surges 18% on Positive Phase 1 Data for OV329 Epilepsy Drug

Ovid Therapeutics surges 18% after Phase 1 data shows OV329 epilepsy drug eliminated safety concerns. Company secures $60M to fund Phase 2 trials.
OVIDbiotechprivate placement
The Motley FoolThe Motley Fool··Eric Volkman

NeuroPace Beats Earnings Expectations, But 2026 Outlook Cools Rally

NeuroPace shares rose nearly 1% after Q4 earnings beat expectations with $26.6M revenue (24% YoY growth) and narrowed losses, though 2026 guidance disappointed investors.
NPCEnet lossrevenue growth